Host Modulation by Ibraheem, Wael I. & Preethanath, Reghunathan S.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Host Modulation
Wael I. Ibraheem and Reghunathan S. Preethanath
Abstract
Host modulation is considered to be new research area in dentistry. In medi-
cine, host modulation was introduced way before dentistry in treating arthritis 
and osteoporosis. It is mainly focusing on the host part during host-bacteria 
interaction. Although there are many agents introduced for this purpose, the most 
well-studied host modulation therapy in dentistry is doxycycline. It shows less 
tissue destruction when used for few months along with periodontal therapy. It 
has anticollagenase properties which shows a promising effect when used to treat 
chronic inflammation.
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1. Introduction
Host modulation therapy is a newly introduced term to the field of dentistry. 
Host refers to the body hosting the disease while modulation refers to changing the 
status of something in response to external modifier.
In periodontal diseases, bacteria/microbes are the main pathogen in initiating 
the disease while the host is the body hosting the bacteria. Host modulation therapy 
is the chemical agent that can be used as an adjunct to the systematized periodontal 
therapy to improve the diseased state and inhibit the tissue destruction. As proved 
in many studies, bacteria cause direct tissue destruction by releasing enzymes and 
other virulent factors and indirectly by letting the host tissue to release collagenases 
which in turn destruct the tissue. Host modulation is working on the indirect arm of 
this process.
Host modulation was introduced in dentistry by William [1] and Golub et al. [2] 
in the 1990s. Both discussed the idea of having a chemical agent that modulate the 
host response and improve the periodontal health. The response to the periodontal 
disease as well as the progression of the periodontal disease varies considerably 
among individuals. Some patients are susceptible to a disease more than others 
which make, the host modulation therapy preferable in such cases.
Host modulation can be used to reduce levels of enzymes, collagenases, and 
proinflammatory cytokines. Moreover, it can modify osteoclast and osteoblast 
activities (Figure 1). It has a role in modifiable risk factors (e.g., smoking, diabetes) 
and unmodifiable risk factors (e.g., genetic susceptibility) as it help the body to 
overcome those risk factors. In systemic host modulation, it has the effect on mul-
tiple sites on the oral cavity with ‘sub-antimicrobial-dose doxycycline’ (SDD) and 
locally with agents such as bone morphogenic proteins (BMP) to improve wound 
healing at the surgical site.
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2. Systemic host modulation
Various medications which are used for host modulation therapy are adminis-
tered orally.
2.1 Bisphosphonates
Bisphosphonate is an agent that is used to inhibit bone resorption by inter-
fering with osteoclasts. The actual mechanism of action is yet unclear. Some 
researches show that bisphosphonate interfere with osteoclast cellular adenosine 
triphosphate (ATPs) [3]. Bisphosphonate possesses anticollagenase properties [4]. 
Bisphosphonates is helpful in periodontal disease associated with bone loss.
In an animal study, bisphosphonate shows more bone density in beagle dogs 
using alendronate [5]. Complications associated with using bisphosphonate are 
mainly bisphosphonate-related osteonecrosis of the jaw (BRONJ). It is mainly 
associated with intravenous administration of bisphosphonate [6]. Bisphosphonate 
is not yet been approved as host modulation therapy for periodontitis.
2.2 Nonsteroidal anti-inflammatory drugs
NSAIDs decrease the production of prostaglandins (PGE). PGE2 is produced 
by different cells such as neutrophils and fibroblast in response to lipo-poly sac-
charide. It has been shown that PGE2 is elevated in periodontitis in response to 
bacteria compared to non-periodontitis cases [7]. By reducing PGE2 production, 
inflammation also subsides in periodontal disease. One study showed lower levels 
of matrix metalloproteinase enzymes (MMP-8) at the gingival crevicular fluid 
(GCF) after administration of NSAIDs [8]. Some studies showed that NSAIDs such 
as indomethacin [9], flurbiprofen [10], and naproxen [11] show reduced bone loss 
when used for a period up to 3 years. These are the non-selective NSAIDs that have 
been investigated in research as host modulation therapy. The main side effect when 
NSAIDs are used for prolonged period as host modulation therapy includes gastro-
intestinal pain and ulcer, bleeding, and renal and hepatic impairment.
Using selective cyclooxygenase-2 (COX-2) inhibitor could be a promising solu-
tion to the side effects of non-selective NSAIDs (Figure 2).
Figure 1. 
The effect of different systemic host modulation therapy agents and their target during gingivitis and 
periodontitis.
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Some studies administering selective NSAIDs showed less PGE2 in human 
periodontal tissues [12]. On the other hand, selective NSAIDs reported side effects 
such as myocardial infarction. NSAIDs also show some rebound effects when the 
usage stopped which resulted in more tissue destruction afterward [13]. NSAIDs are 
not yet been approved as host modulation therapy for periodontitis.
2.3 Sub-antimicrobial-dose doxycycline
Sub-antimicrobial-dose doxycycline (SDD) is the only host modulation therapy 
approved by the U.S. Food and Drug Administration (FDA) and accepted by the 
American Dental Association (ADA). SDD (Periostat) is usually administered as 
20 mg twice daily for a period of 3 months. Less than 3 months period was showing 
rebound effect of collagenase levels as the benefit of SDD is not yet been applied at the 
tissue [14]. In many cases, physicians are prescribing the medication for a period up to 
9 months and regular follow up every 3 months to evaluate the effect of the medication.
SDD has an anticollagenase effect and inhibit osteoclast and proinflammatory 
cytokines. The effect of SDD is below the detection of bacteria which will not cause 
any resistance in the future. Moreover, there is no rebound effect registered after 
discontinuing the medication. The significant clinical effect of SDD compared to 
placebo in 266 patients when used as an adjunct to scaling and root planing (SRP) in 
periodontitis patients has been reported in a study [15]. Another study was showing 
the effect of SDD as an adjunct to SRP with smokers having periodontitis [16].
Large number of MMPs is released to the periodontal tissues during inflamma-
tion by different cells. MMP-8 and MMP-9 are major enzymes released from neutro-
phils during inflammation which cause tissue destruction through degrading type I 
collagen [17, 18]. The release of MMPs leads to progressive destruction of periodontal 
tissues which is related to the large number of neutrophils during inflammation.
Figure 2. 
Cyclooxygenase enzyme converts arachidonic acid to prostaglandins. COX-1 maintains the homeostatic 
functions at the body while COX-2 contributes more with the inflammation.
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3. Local host modulation
3.1 Enamel matrix proteins, growth factors, and bone morphogenetic proteins
The locally administered host modulation therapy is used mainly to improve 
wound healing, increase bone formation, and to produce new periodontal tissue 
including periodontal ligament and cementum. They have been applied locally 
along with periodontal surgery. The FDA approved local host modulatory agents 
includes enamel matrix proteins (Emdogain), recombinant human platelet-derived 
growth factor-BB (GEM 21S), and BMP-2 (rhBMP-2 [Infuse]). These materials 
have been proved to provide some clinical benefits when used during periodontal 
surgical procedures. The focus of this chapter is on the non-surgical therapy of 
gingivitis and periodontitis.
4. Conclusions
To summarize, patient selection and motivation to do periodontal therapy is the 
key to start host modulation therapy. Moreover, medical status of the patient would 
affect the outcome of the treatment.
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